Updates are available Correction dated 2022-05-17
Click to view Correction: https://doi.org/10.1186/s12883-022-02701-6
-
Authors
Bonanni, Paolo https://orcid.org/0000-0002-9448-9059
Gambardella, Antonio https://orcid.org/0000-0001-7384-3074
Tinuper, Paolo https://orcid.org/0000-0002-0588-3063
Acone, Benedetto https://orcid.org/0000-0002-7481-2496
Perucca, Emilio https://orcid.org/0000-0001-8703-223X
Coppola, Giangennaro https://orcid.org/0000-0002-9574-0081
- License Information
-
More Information
Article History
Received: 8 August 2021
Accepted: 14 October 2021
First Online: 26 October 2021
Change Date: 17 May 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s12883-022-02701-6
Declarations
:
: Not applicable.
: Not applicable.
: AG received speaker’s or consultancy fees from Eisai, UCB Pharma and Zogenix; BA received speaker’s or consultancy fees for projects sponsored by Eisai, Astra Zeneca, Novartis, Gilead, Sanofi, Sandoz, Sobi, MSD, Angelini, AlfaSigma, Janssen, Kyowa Kirin, Abiogen, Amgen, Teva; EP received speaker’s or consultancy fees from Arvelle, Biogen, Corlieve, Eisai, GW Pharma, Sanofi, Sun Pharma, UCB Pharma, Xenon Pharma and Zogenix. GG received speaker’s or consultancy fees from Eisai and Humana; PB received speaker’s or consultancy fees from Eisai, LivaNova, Lusofarmaco, Proveca; BIAL, Roche; PT received speaker’s or consultancy fees from Arvelle, Eisai, GW Pharma, LivaNova, UCB Pharma, Xenon Pharma and Zogenix.
